DaVita Inc. Files 2024 10-K, Discloses Debt Maturities

TL;DR

DaVita's 2024 10-K is out. Lots of debt coming due soon, rates vary. Keep an eye on cash flow.

AI Summary

DaVita Inc. filed its 2024 10-K on February 13, 2025, reporting on its fiscal year ending December 31, 2024. The company, a provider of kidney dialysis services, detailed its financial performance and operational status. Key financial figures and debt obligations were disclosed, including various tranches of debt maturing between 2025 and 2027, with interest rates ranging from 1.10% to 4.70%.

Why It Matters

This filing provides investors and analysts with a comprehensive overview of DaVita's financial health and future obligations, crucial for assessing the company's stability and investment potential.

Risk Assessment

Risk Level: medium — The company has significant debt obligations maturing in the near term, which could pose a risk if not managed effectively.

Key Numbers

• 2024 — Fiscal Year (Reporting period for the 10-K)
• 20250213 — Filing Date (Date the 10-K was submitted to the SEC)
• 1.10% — Lowest Debt Interest Rate (Represents the lowest rate on disclosed debt obligations)
• 4.70% — Highest Debt Interest Rate (Represents the highest rate on disclosed debt obligations)
• 2025-2027 — Debt Maturity Window (Period during which significant debt obligations are due)

Key Players & Entities

• DAVITA INC. (company) — Filer of the 10-K
• 20241231 (date) — Fiscal year end
• 20250213 (date) — Filing date
• DENVER (location) — Company headquarters city
• DE (location) — State of incorporation
• 1.10% (dollar_amount) — Lowest interest rate on debt
• 4.70% (dollar_amount) — Highest interest rate on debt
• 2025 (date) — Earliest debt maturity year
• 2027 (date) — Latest debt maturity year

FAQ

Key Financial Figures

• $0.001 — nge on which registered: Common Stock, $0.001 par value DVA New York Stock Exchange

Filing Documents

• dva-20241231.htm (10-K) — 3083KB
• ex106-fifthamendmenttocred.htm (EX-10.6) — 67KB
• ex191-dvainsidertradingpol.htm (EX-19.1) — 89KB
• dva-123124ex211.htm (EX-21.1) — 368KB
• dva-123124ex231.htm (EX-23.1) — 2KB
• dva-123124ex31110xk.htm (EX-31.1) — 9KB
• dva-123124ex31210xk.htm (EX-31.2) — 9KB
• dva-123124ex32110xk.htm (EX-32.1) — 6KB
• dva-123124ex32210xk.htm (EX-32.2) — 5KB
• dva-20241231_g1.gif (GRAPHIC) — 50KB
• dva-20241231_g2.jpg (GRAPHIC) — 40KB
• dva-20241231_g3.jpg (GRAPHIC) — 808KB
• image_1a.jpg (GRAPHIC) — 34KB
• 0000927066-25-000012.txt ( ) — 18717KB
• dva-20241231.xsd (EX-101.SCH) — 106KB
• dva-20241231_cal.xml (EX-101.CAL) — 137KB
• dva-20241231_def.xml (EX-101.DEF) — 586KB
• dva-20241231_lab.xml (EX-101.LAB) — 1309KB
• dva-20241231_pre.xml (EX-101.PRE) — 934KB
• dva-20241231_htm.xml (XML) — 2445KB

Risk Factors

Item 1A. Risk Factors 24

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 53

Cybersecurity

Item 1C. Cybersecurity 53

Properties

Item 2. Properties 55

Legal Proceedings

Item 3. Legal Proceedings 55

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 55 PART II.

Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 56

Reserved

Item 6. Reserved 56

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 57

Quantitative and Qualitative Disclosures about Market Risk

Item 7A. Quantitative and Qualitative Disclosures about Market Risk 79

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 79

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 79

Controls and Procedures

Item 9A. Controls and Procedures 80

Other Information

Item 9B. Other Information 80

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 80 PART III.

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 81

Executive Compensation

Item 11. Executive Compensation 81

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 81

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 82

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 82 PART IV.

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules 83

Form 10-K Summary

Item 16. Form 10-K Summary 83 Exhibit Index 1 of 4

Signatures

Signatures S-1 PART I

Business

Item 1. Business Unless otherwise indicated in this report "DaVita", "the Company" "we", "us", "our" and other similar terms refer to DaVita Inc. and its consolidated subsidiaries. Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are made available free of charge through our website, located at http://www.davita.com , as soon as reasonably practicable after the reports are filed with or furnished to the Securities and Exchange Commission (SEC). The SEC also maintains a website at http://www.sec.gov where these reports and other information about us can be obtained. The contents of our website are not incorporated by reference into this report. Overview of DaVita Inc. DaVita is a leading healthcare provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, we have been a leader in clinical quality and innovation for 25 years. We care for patients at every stage and setting along their kidney health journey – from earlier diagnosis and prevention through supporting the transplant process. This includes ensuring they are supported at home, in our dialysis centers, in the hospital and/or skilled nursing facilities. In our unwavering pursuit of a healthier tomorrow, we strive to reimagine what high quality care looks like: more preventative, better integrated, improved outcomes at the lowest total cost, and personalized at scale to deliver a better tomorrow regardless of location, insurance status or other factors. Our caring culture fuels our continuous drive toward achieving our mission to be the provider, partner and employer of choice. Defining chronic kidney disease There are five stages of chronic kidney disease (CKD). These stages are generally based on how well the kidneys work to filter waste and extr

View Full Filing

View this 10-K filing on SEC EDGAR